The shadow of generic competition has repeatedly loomed around copyright’s famous drug, PDE5 Inhibitor, sparking questions about the prospects of related drug ventures. While initial periods saw significant gains, the exclusivity end has created the way for less expensive alternatives, likely lowering earnings and posing a real risk for stakehold